Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News LogicBio Therapeutics Inc. LOGC

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.


Recent & Breaking News (NDAQ:LOGC)

LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide(TM) Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress

GlobeNewswire October 16, 2019

Horizon Technology Finance Provides Third Quarter 2019 Portfolio Update

PR Newswire October 9, 2019

LogicBio Therapeutics to Present at October Conferences

GlobeNewswire September 26, 2019

LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates

GlobeNewswire August 13, 2019

LogicBio Therapeutics Receives Rare Pediatric Disease Designation for LB-001 for the Treatment of Methylmalonic Acidemia

GlobeNewswire July 16, 2019

LogicBio Secures Up To $20 Million Debt Facility with Oxford Finance LLC and Horizon Technology Finance

GlobeNewswire July 2, 2019

LogicBio to Present at the Jefferies 2019 Healthcare Conference

GlobeNewswire May 30, 2019

LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates

GlobeNewswire May 14, 2019

LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia

GlobeNewswire April 29, 2019

LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide(TM) Platform Development and Advancement of Lead Program into Clinic

GlobeNewswire April 22, 2019